A US Supreme Court fight over how branded drugs’ makers must plead induced infringement in “skinny-label” patent suits could ...
While off-label use may be permissible, contraindicated use still has a strong regulatory boundary as reinforced by FDA guidance finalized in 2025.
The U.S. Department of Justice has agreed to withdraw significant portions of a subpoena that sought sensitive medical records from Children’s Hospital Los An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback